We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Among those deemed “treatment sensitive,” 69.4% ...

Please provide your email address to receive an email when new articles are posted on . Monthly seizure frequency percentage reduction was 68.73% for the entire study cohort. For those followed up in ...

In most people, every cell in their body contains the same genetic information. However, sometimes people can have two or more genetically different sets of cells. This usually happens during fetal ...

Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BOSTON -- Implantation of so-called inhibitory neurons helped ...

University of California San Diego is conducting new, Phase 2/3 national epilepsy clinical research trials, called Rise, to study BHV-7000, a novel investigational therapy, in focal epilepsy.

(RTTNews) - Shares of Xenon Pharmaceuticals Inc. (XENE) closed Monday's trading at an all-time high of $31.50, gaining more than 100%, thanks to promising mid-stage data for focal epilepsy drug ...

Patients with focal nonmotor seizures experience a "disproportionate delay to diagnosis" compared with those with focal motor seizures, especially among teens, new research suggests. Retrospective ...

Adding the novel drug XEN1101 to current antiseizure regimens significantly decreases seizures in patients with treatment-resistant focal epilepsy and can safely be taken at its highest dose, results ...

Rapport Therapeutics, a company whose neuroscience technology comes from Johnson & Johnson, joined the public markets Friday, raising $154 million for proof-of-concept testing of a lead program in ...

After 3 months on cenobamate maintenance therapy, 49.3% of patients achieved at least a 50% reduction in seizure frequency. Patients with drug-resistant epilepsy (DRE) treated with cenobamate ...

More than 3.4 million people in the United States have epilepsy, so it is a relatively common diagnosis. In fact, it is the fourth-most common neurologic condition in the world. November is National ...

(RTTNews) - Shares of Xenon Pharmaceuticals Inc. (XENE) closed Monday's trading at an all-time high of $31.50, gaining more than 100%, thanks to promising mid-stage data for focal epilepsy drug ...